Prurigo Nodularis - Market Insights, Epidemiology and Market Forecast-2027
This report can be delivered to the clients within 24 hours
DelveInsight’s ‘Prurigo Nodularis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Prurigo Nodularis from 2016 to 2027 segmented by the US, EU-5 countries and Japan. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Prurigo Nodularis - Disease Understanding and Treatment Algorithm
The DelveInsight Prurigo Nodularis market report gives the thorough understanding of the Prurigo Nodularis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, treatment algorithms and treatment guidelines in the US, Europe, and Japan.
Prurigo Nodularis Epidemiology
The Prurigo Nodularis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented into four parts: Total Prevalent Population of Prurigo Nodularis, Total Diagnosed Prevalence of Prurigo Nodularis, Type-Specific Prevalent Population of Prurigo Nodularis and Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in 7 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan].
According to DelveInsight, the total prevalent cases of Prurigo Nodularis was 686,375 in 2016 in 7MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM, United States accounts for highest prevalent cases of Prurigo Nodularis with 256,941 prevalent cases in 2016.
Prurigo Nodularis Drug Chapters
This segment of the House Dust Mite Allergy report encloses the detailed analysis of emerging drugs along with a key cross competition. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Prurigo Nodularis (PN) is a chronic, bothersome-to-debilitating disease of the skin, usually seen as multiple, intense pruritic, and excoriated nodules erupting on the surfaces of the extremities with intense itching or rubbing. Prurigo Nodules are cutaneous lesions often produced by repetitive scratching hence the nickname “picker’s nodules”, which may occur as sequel of chronic pruritus or neurotic excoriations.
Prurigo Nodularis Market Outlook
The Prurigo Nodularis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The report provides global market share of Prurigo Nodularis i.e., 7 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)] and Japan. In 2016, global market size of Prurigo Nodularis was USD 133.65 million and, is expected to grow at a CAGR of XX% during the forecast period of 2018-2027.
The region-wise market size for Prurigo Nodularis in US, EU-5 countries (Germany, France, Italy, Spain and the U.K.) and Japan shows highest market size in US, followed by Germany.
Prurigo Nodularis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Prurigo Nodularis Report Insights
DelveInsight’s ‘Prurigo Nodularis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Prurigo Nodularis from 2016 to 2027 segmented by the US, EU-5 countries and Japan. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Prurigo Nodularis - Disease Understanding and Treatment Algorithm
The DelveInsight Prurigo Nodularis market report gives the thorough understanding of the Prurigo Nodularis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, treatment algorithms and treatment guidelines in the US, Europe, and Japan.
Prurigo Nodularis Epidemiology
The Prurigo Nodularis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented into four parts: Total Prevalent Population of Prurigo Nodularis, Total Diagnosed Prevalence of Prurigo Nodularis, Type-Specific Prevalent Population of Prurigo Nodularis and Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in 7 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan].
According to DelveInsight, the total prevalent cases of Prurigo Nodularis was 686,375 in 2016 in 7MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM, United States accounts for highest prevalent cases of Prurigo Nodularis with 256,941 prevalent cases in 2016.
Prurigo Nodularis Drug Chapters
This segment of the House Dust Mite Allergy report encloses the detailed analysis of emerging drugs along with a key cross competition. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Prurigo Nodularis (PN) is a chronic, bothersome-to-debilitating disease of the skin, usually seen as multiple, intense pruritic, and excoriated nodules erupting on the surfaces of the extremities with intense itching or rubbing. Prurigo Nodules are cutaneous lesions often produced by repetitive scratching hence the nickname “picker’s nodules”, which may occur as sequel of chronic pruritus or neurotic excoriations.
Prurigo Nodularis Market Outlook
The Prurigo Nodularis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The report provides global market share of Prurigo Nodularis i.e., 7 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)] and Japan. In 2016, global market size of Prurigo Nodularis was USD 133.65 million and, is expected to grow at a CAGR of XX% during the forecast period of 2018-2027.
The region-wise market size for Prurigo Nodularis in US, EU-5 countries (Germany, France, Italy, Spain and the U.K.) and Japan shows highest market size in US, followed by Germany.
Prurigo Nodularis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Prurigo Nodularis Report Insights
- Patient Population
- Market Size and Trends
- Pipeline Analysis
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Prurigo Nodularis market
- Organize sales and marketing efforts by identifying the best opportunities for Prurigo Nodularis market
- To understand the future market competition in the Prurigo Nodularis market.
1. KEY INSIGHTS
2. PRURIGO NODULARIS MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of Prurigo Nodularis in 2017
2.2. Market Share (%) Distribution of Prurigo Nodularis in 2027
2.3. Total Market Share (%) Distribution of Prurigo Nodularis by therapies in 2016
2.4. Total Market Share (%) Distribution of Prurigo Nodularis by therapies in 2027
3. PRURIGO NODULARIS: DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Classification
3.3. Clinical Signs and Symptoms
3.4. Pathophysiology
3.5. ETIOLOGY
3.6. Diagnosis
3.7. Management
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
5. 7MM TOTAL PREVALENT POPULATION OF PRURIGO NODULARIS
6. 7MM TOTAL DIAGNOSED PREVALENT POPULATION OF PRURIGO NODULARIS
7. COUNTRY WISE-EPIDEMIOLOGY OF PRURIGO NODULARIS
7.1. United States
7.1.1. Assumptions and Rationale
7.1.2. Total Prevalent Population of Prurigo Nodularis in the United States
7.1.3. Total Diagnosed Prevalence of Prurigo Nodularis in the United States
7.1.4. Type-Specific Diagnosed Prevalent Population of Prurigo Nodularis in the United States
7.1.5. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in the United States
7.2. EU5 Countries
7.2.1. Assumptions and Rationale
7.3. Germany
7.3.1. Total Prevalent Population of Prurigo Nodularis in Germany
7.3.2. Total Diagnosed Prevalence of Prurigo Nodularis in Germany
7.3.3. Type -Specific Diagnosed Prevalent Population of Prurigo Nodularis in Germany
7.3.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Germany
7.4. France
7.4.1. Total Prevalent Population of Prurigo Nodularis in France
7.4.2. Total Diagnosed Prevalence of Prurigo Nodularis in France
7.4.3. Type -Specific Prevalent Population of Prurigo Nodularis in France
7.4.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in France
7.5. Italy
7.5.1. Total Prevalent Population of Prurigo Nodularis in Italy
7.5.2. Total Diagnosed Prevalence of Prurigo Nodularis in Italy
7.5.3. Type -Specific Diagnosed Prevalent Population of Prurigo Nodularis in Italy
7.5.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Italy
7.6. Spain
7.6.1. Total Prevalent Population of Prurigo Nodularis in Spain
7.6.2. Total Diagnosed Prevalence of Prurigo Nodularis in Spain
7.6.3. Type -Specific Diagnosed Prevalent Population of Prurigo Nodularis in Spain
7.6.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Spain
7.7. United Kingdom
7.7.1. Total Prevalent Population of Prurigo Nodularis in the United Kingdom
7.7.2. Total Diagnosed Prevalence of Prurigo Nodularis in the United Kingdom
7.7.3. Type -Specific Diagnosed Prevalent Population of Prurigo Nodularis in the United Kingdom
7.7.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in the United Kingdom
7.8. Japan
7.8.1. Total Prevalent Population of Prurigo Nodularis in Japan
7.8.2. Total Diagnosed Prevalence of Prurigo Nodularis in Japan
7.8.3. Type -Specific Diagnosed Prevalent Population of Prurigo Nodularis in Japan
7.8.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Japan
7.9. Treatment of Prurigo Nodularis
7.9.1. Topical Therapy
7.9.2. Phototherapy
7.9.3. Systemic therapy
8. EUROPEAN GUIDELINES ON PRURIGO NODULARIS
8.1. General principles
8.2. Systemic therapy
9. FDA RECOMMENDATIONS FOR PRURIGO NODULARIS TREATMENT
9.1. Diagnostic work up
9.2. Treatment Recommendations
10. UNMET NEEDS
11. EMERGING DRUGS
11.1. Key Cross Competition
11.2. Serlopitant: Menlo Therapeutics
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.2.5. Advantages and Disadvantages
11.2.6. Product Profile
11.3. Nalbuphine ER: Trevi Therapeutics
11.3.1. Product Description
11.3.2. Other Development Activities
11.3.3. Clinical Development
11.3.4. Safety and Efficacy
11.3.5. Advantages and Disadvantages
11.3.6. Product Profile
11.4. Nemolizumab: Galderma
11.4.1. Product Description
11.4.2. Other Development Activities
11.4.3. Clinical Development
11.4.4. Advantages and Disadvantages
11.4.5. Product Profile
11.5. Apremilast: Celgene
11.5.1. Product Description
11.5.2. Other Development Activities
11.5.3. Clinical Development
11.5.4. Safety and Efficacy
11.5.5. Advantages and Disadvantages
11.5.6. Product Profile
11.6. M 118103: Maruho
11.6.1. Product Description
11.6.2. Other Development Activities
11.6.3. Clinical Development
11.6.4. Clinical Trials Information
11.6.5. Product Profile
12. PRURIGO NODULARIS: 7 MAJOR MARKET ANALYSIS
12.1. Key Findings
12.2. Market Size of Prurigo Nodularis in 7MM
12.3. Market Size of Prurigo Nodularis by therapies in 7MM
13. THE UNITED STATES MARKET OUTLOOK
13.1. United States Market Size
13.1.1. Total Market size of Prurigo Nodularis in the United States
13.1.2. Market size of Prurigo Nodularis by Therapies in the United States
14. EU-5 COUNTRIES: MARKET OUTLOOK
14.1. Germany
14.1.1. Total Market size of Prurigo Nodularis in Germany
14.1.2. Market size of Prurigo Nodularis by Therapies in Germany
14.2. France
14.2.1. Total Market size of Prurigo Nodularis in France
14.2.2. Market size of Prurigo Nodularis by Therapies in France
14.3. Italy
14.3.1. Total Market size of Prurigo Nodularis in Italy
14.3.2. Market size of Prurigo Nodularis by Therapies in Italy
14.4. Spain
14.4.1. Total Market Size of Prurigo Nodularis in Spain
14.4.2. Market size of Prurigo Nodularis by Therapies in Spain
14.5. United Kingdom
14.5.1. Total Market size of Prurigo Nodularis in the United Kingdom
14.5.2. Market size of Prurigo Nodularis by Therapies in the United Kingdom
14.6. Japan: Market Outlook
14.6.1. Total Market size of Prurigo Nodularis in Japan
14.6.2. Market size of Prurigo Nodularis by Therapies in Japan
15. MARKET DRIVERS
16. MARKET BARRIERS
17. APPENDIX
17.1. Report Methodology
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
2. PRURIGO NODULARIS MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of Prurigo Nodularis in 2017
2.2. Market Share (%) Distribution of Prurigo Nodularis in 2027
2.3. Total Market Share (%) Distribution of Prurigo Nodularis by therapies in 2016
2.4. Total Market Share (%) Distribution of Prurigo Nodularis by therapies in 2027
3. PRURIGO NODULARIS: DISEASE BACKGROUND AND OVERVIEW
3.1. Introduction
3.2. Classification
3.3. Clinical Signs and Symptoms
3.4. Pathophysiology
3.5. ETIOLOGY
3.6. Diagnosis
3.7. Management
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
5. 7MM TOTAL PREVALENT POPULATION OF PRURIGO NODULARIS
6. 7MM TOTAL DIAGNOSED PREVALENT POPULATION OF PRURIGO NODULARIS
7. COUNTRY WISE-EPIDEMIOLOGY OF PRURIGO NODULARIS
7.1. United States
7.1.1. Assumptions and Rationale
7.1.2. Total Prevalent Population of Prurigo Nodularis in the United States
7.1.3. Total Diagnosed Prevalence of Prurigo Nodularis in the United States
7.1.4. Type-Specific Diagnosed Prevalent Population of Prurigo Nodularis in the United States
7.1.5. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in the United States
7.2. EU5 Countries
7.2.1. Assumptions and Rationale
7.3. Germany
7.3.1. Total Prevalent Population of Prurigo Nodularis in Germany
7.3.2. Total Diagnosed Prevalence of Prurigo Nodularis in Germany
7.3.3. Type -Specific Diagnosed Prevalent Population of Prurigo Nodularis in Germany
7.3.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Germany
7.4. France
7.4.1. Total Prevalent Population of Prurigo Nodularis in France
7.4.2. Total Diagnosed Prevalence of Prurigo Nodularis in France
7.4.3. Type -Specific Prevalent Population of Prurigo Nodularis in France
7.4.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in France
7.5. Italy
7.5.1. Total Prevalent Population of Prurigo Nodularis in Italy
7.5.2. Total Diagnosed Prevalence of Prurigo Nodularis in Italy
7.5.3. Type -Specific Diagnosed Prevalent Population of Prurigo Nodularis in Italy
7.5.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Italy
7.6. Spain
7.6.1. Total Prevalent Population of Prurigo Nodularis in Spain
7.6.2. Total Diagnosed Prevalence of Prurigo Nodularis in Spain
7.6.3. Type -Specific Diagnosed Prevalent Population of Prurigo Nodularis in Spain
7.6.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Spain
7.7. United Kingdom
7.7.1. Total Prevalent Population of Prurigo Nodularis in the United Kingdom
7.7.2. Total Diagnosed Prevalence of Prurigo Nodularis in the United Kingdom
7.7.3. Type -Specific Diagnosed Prevalent Population of Prurigo Nodularis in the United Kingdom
7.7.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in the United Kingdom
7.8. Japan
7.8.1. Total Prevalent Population of Prurigo Nodularis in Japan
7.8.2. Total Diagnosed Prevalence of Prurigo Nodularis in Japan
7.8.3. Type -Specific Diagnosed Prevalent Population of Prurigo Nodularis in Japan
7.8.4. Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Japan
7.9. Treatment of Prurigo Nodularis
7.9.1. Topical Therapy
7.9.2. Phototherapy
7.9.3. Systemic therapy
8. EUROPEAN GUIDELINES ON PRURIGO NODULARIS
8.1. General principles
8.2. Systemic therapy
9. FDA RECOMMENDATIONS FOR PRURIGO NODULARIS TREATMENT
9.1. Diagnostic work up
9.2. Treatment Recommendations
10. UNMET NEEDS
11. EMERGING DRUGS
11.1. Key Cross Competition
11.2. Serlopitant: Menlo Therapeutics
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.2.5. Advantages and Disadvantages
11.2.6. Product Profile
11.3. Nalbuphine ER: Trevi Therapeutics
11.3.1. Product Description
11.3.2. Other Development Activities
11.3.3. Clinical Development
11.3.4. Safety and Efficacy
11.3.5. Advantages and Disadvantages
11.3.6. Product Profile
11.4. Nemolizumab: Galderma
11.4.1. Product Description
11.4.2. Other Development Activities
11.4.3. Clinical Development
11.4.4. Advantages and Disadvantages
11.4.5. Product Profile
11.5. Apremilast: Celgene
11.5.1. Product Description
11.5.2. Other Development Activities
11.5.3. Clinical Development
11.5.4. Safety and Efficacy
11.5.5. Advantages and Disadvantages
11.5.6. Product Profile
11.6. M 118103: Maruho
11.6.1. Product Description
11.6.2. Other Development Activities
11.6.3. Clinical Development
11.6.4. Clinical Trials Information
11.6.5. Product Profile
12. PRURIGO NODULARIS: 7 MAJOR MARKET ANALYSIS
12.1. Key Findings
12.2. Market Size of Prurigo Nodularis in 7MM
12.3. Market Size of Prurigo Nodularis by therapies in 7MM
13. THE UNITED STATES MARKET OUTLOOK
13.1. United States Market Size
13.1.1. Total Market size of Prurigo Nodularis in the United States
13.1.2. Market size of Prurigo Nodularis by Therapies in the United States
14. EU-5 COUNTRIES: MARKET OUTLOOK
14.1. Germany
14.1.1. Total Market size of Prurigo Nodularis in Germany
14.1.2. Market size of Prurigo Nodularis by Therapies in Germany
14.2. France
14.2.1. Total Market size of Prurigo Nodularis in France
14.2.2. Market size of Prurigo Nodularis by Therapies in France
14.3. Italy
14.3.1. Total Market size of Prurigo Nodularis in Italy
14.3.2. Market size of Prurigo Nodularis by Therapies in Italy
14.4. Spain
14.4.1. Total Market Size of Prurigo Nodularis in Spain
14.4.2. Market size of Prurigo Nodularis by Therapies in Spain
14.5. United Kingdom
14.5.1. Total Market size of Prurigo Nodularis in the United Kingdom
14.5.2. Market size of Prurigo Nodularis by Therapies in the United Kingdom
14.6. Japan: Market Outlook
14.6.1. Total Market size of Prurigo Nodularis in Japan
14.6.2. Market size of Prurigo Nodularis by Therapies in Japan
15. MARKET DRIVERS
16. MARKET BARRIERS
17. APPENDIX
17.1. Report Methodology
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Total Prevalent Population of Prurigo Nodularis in the 7MM (2016-2027)
Table 2: Total Diagnosed Prevalent Population of Prurigo Nodularis in the 7MM (2016-2027)
Table 3: Total Prevalent Population of Prurigo Nodularis in the United States (2016-2027)
Table 4: Total Diagnosed Prevalence of Prurigo Nodularis in the United States (2016-2027)
Table 5: Type-Specific Prevalent Population of Prurigo Nodularis in the United States (2016-2027)
Table 6: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in the United States (2016-2027)
Table 7: Total Prevalent Population of Prurigo Nodularis in Germany (2016-2027)
Table 8: Total Diagnosed Prevalence of Prurigo Nodularis in Germany (2016-2027)
Table 9: Type-Specific Prevalent Population of Prurigo Nodularis in Germany (2016-2027)
Table 10: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Germany (2016-2027)
Table 11: Total Prevalent Population of Prurigo Nodularis in France (2016-2027)
Table 12: Total Diagnosed Prevalence of Prurigo Nodularis in France (2016-2027)
Table 13: Type-Specific Prevalent Population of Prurigo Nodularis in France (2016-2027)
Table 14: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in France (2016-2027)
Table 15: Total Prevalent Population of Prurigo Nodularis in Italy (2016-2027)
Table 16: Total Diagnosed Prevalence of Prurigo Nodularis in Italy (2016-2027)
Table 17: Type-Specific Prevalent Population of Prurigo Nodularis in Italy (2016-2027)
Table 18: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Italy (2016-2027)
Table 19: Total Prevalent Population of Prurigo Nodularis in Spain (2016-2027)
Table 20: Total Diagnosed Prevalence of Prurigo Nodularis in Spain (2016-2027)
Table 21: Type-Specific Prevalent Population of Prurigo Nodularis in Spain (2016-2027)
Table 22: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Spain (2016-2027)
Table 23: Total Prevalent Population of Prurigo Nodularis in the United Kingdom (2016-2027)
Table 24: Total Diagnosed Prevalence of Prurigo Nodularis in the United Kingdom (2016-2027)
Table 25: Type-Specific Prevalent Population of Prurigo Nodularis in the United Kingdom (2016-2027)
Table 26: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in the UK (2016-2027)
Table 27: Total Prevalent Population of Prurigo Nodularis in Japan (2016-2027)
Table 28: Total Diagnosed Prevalence of Prurigo Nodularis in Japan (2016-2027)
Table 29: Type-Specific Prevalent Population of Prurigo Nodularis in Japan (2016-2027)
Table 30: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Japan (2016-2027)
Table 31: Comparison of emerging drugs under development
Table 32: Serlopitant, Clinical Trial Description, 2018
Table 33: Nalbuphine ER, Clinical Trial Description, 2018
Table 34: ALLN-177, Clinical Trial Description, 2017
Table 35: Apremilast, Clinical Trial Description, 2018
Table 36: Apremilast, Clinical Trial Description, 2018
Table 37: 7 Major Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 38: Market Size of Prurigo Nodularis by therapies in the 7MM in USD Million (2016-2027)
Table 39: United States Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 40: Market Size of Prurigo Nodularis by therapies in the US in USD Million (2016-2027)
Table 41: Germany Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 42: Market Size of Prurigo Nodularis by therapies in Germany in USD Million (2016-2027)
Table 43: France Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 44: Market Size of Prurigo Nodularis by therapies in France in USD Million (2016-2027)
Table 45: Italy Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 46: Market Size of Prurigo Nodularis by therapies in Italy in USD Million (2016-2027)
Table 47: Spain Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 48: Market Size of Prurigo Nodularis by therapies in Spain in USD Million (2016-2027)
Table 49: United Kingdom Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 50: Market Size of Prurigo Nodularis by therapies in the UK in USD Million (2016-2027)
Table 51: Japan Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 52:Market Size of Prurigo Nodularis by therapies in the Japan in USD Million (2016-2027)
Table 1: Total Prevalent Population of Prurigo Nodularis in the 7MM (2016-2027)
Table 2: Total Diagnosed Prevalent Population of Prurigo Nodularis in the 7MM (2016-2027)
Table 3: Total Prevalent Population of Prurigo Nodularis in the United States (2016-2027)
Table 4: Total Diagnosed Prevalence of Prurigo Nodularis in the United States (2016-2027)
Table 5: Type-Specific Prevalent Population of Prurigo Nodularis in the United States (2016-2027)
Table 6: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in the United States (2016-2027)
Table 7: Total Prevalent Population of Prurigo Nodularis in Germany (2016-2027)
Table 8: Total Diagnosed Prevalence of Prurigo Nodularis in Germany (2016-2027)
Table 9: Type-Specific Prevalent Population of Prurigo Nodularis in Germany (2016-2027)
Table 10: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Germany (2016-2027)
Table 11: Total Prevalent Population of Prurigo Nodularis in France (2016-2027)
Table 12: Total Diagnosed Prevalence of Prurigo Nodularis in France (2016-2027)
Table 13: Type-Specific Prevalent Population of Prurigo Nodularis in France (2016-2027)
Table 14: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in France (2016-2027)
Table 15: Total Prevalent Population of Prurigo Nodularis in Italy (2016-2027)
Table 16: Total Diagnosed Prevalence of Prurigo Nodularis in Italy (2016-2027)
Table 17: Type-Specific Prevalent Population of Prurigo Nodularis in Italy (2016-2027)
Table 18: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Italy (2016-2027)
Table 19: Total Prevalent Population of Prurigo Nodularis in Spain (2016-2027)
Table 20: Total Diagnosed Prevalence of Prurigo Nodularis in Spain (2016-2027)
Table 21: Type-Specific Prevalent Population of Prurigo Nodularis in Spain (2016-2027)
Table 22: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Spain (2016-2027)
Table 23: Total Prevalent Population of Prurigo Nodularis in the United Kingdom (2016-2027)
Table 24: Total Diagnosed Prevalence of Prurigo Nodularis in the United Kingdom (2016-2027)
Table 25: Type-Specific Prevalent Population of Prurigo Nodularis in the United Kingdom (2016-2027)
Table 26: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in the UK (2016-2027)
Table 27: Total Prevalent Population of Prurigo Nodularis in Japan (2016-2027)
Table 28: Total Diagnosed Prevalence of Prurigo Nodularis in Japan (2016-2027)
Table 29: Type-Specific Prevalent Population of Prurigo Nodularis in Japan (2016-2027)
Table 30: Severity Specific Diagnosed Prevalent Population of Prurigo Nodularis in Japan (2016-2027)
Table 31: Comparison of emerging drugs under development
Table 32: Serlopitant, Clinical Trial Description, 2018
Table 33: Nalbuphine ER, Clinical Trial Description, 2018
Table 34: ALLN-177, Clinical Trial Description, 2017
Table 35: Apremilast, Clinical Trial Description, 2018
Table 36: Apremilast, Clinical Trial Description, 2018
Table 37: 7 Major Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 38: Market Size of Prurigo Nodularis by therapies in the 7MM in USD Million (2016-2027)
Table 39: United States Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 40: Market Size of Prurigo Nodularis by therapies in the US in USD Million (2016-2027)
Table 41: Germany Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 42: Market Size of Prurigo Nodularis by therapies in Germany in USD Million (2016-2027)
Table 43: France Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 44: Market Size of Prurigo Nodularis by therapies in France in USD Million (2016-2027)
Table 45: Italy Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 46: Market Size of Prurigo Nodularis by therapies in Italy in USD Million (2016-2027)
Table 47: Spain Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 48: Market Size of Prurigo Nodularis by therapies in Spain in USD Million (2016-2027)
Table 49: United Kingdom Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 50: Market Size of Prurigo Nodularis by therapies in the UK in USD Million (2016-2027)
Table 51: Japan Market Size of Prurigo Nodularis in USD Million (2016-2027)
Table 52:Market Size of Prurigo Nodularis by therapies in the Japan in USD Million (2016-2027)
LIST OF FIGURES
Figure 1: Prurigo Nodualris - Butterfly Sign – No Lesion On The Center Of The Back
Figure 2: Total Prevalent Patient Population Of Prurigo Nodularis In The 7mm (2016-2027)
Figure 3: Total Diagnosed Prevalent Patient Population Of Prurigo Nodularis In The 7mm (2016-2027)
Figure 4: Total Prevalent Population Of Prurigo Nodularis In The United States (2016-2027)
Figure 5: Total Diagnosed Prevalence Of Prurigo Nodularis In The United States (2016-2027)
Figure 6: Type-Specific Prevalent Population Of Prurigo Nodularis In The United States (2016-2027)
Figure 7: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In The United States (2016-2027)
Figure 8: Total Prevalent Population Of Prurigo Nodularis In Germany (2016-2027)
Figure 9: Total Diagnosed Prevalence Of Prurigo Nodularis In Germany (2016-2027)
Figure 10: Type-Specific Prevalent Population Of Prurigo Nodularis In Germany (2016-2027)
Figure 11: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In Germany (2016-2027)
Figure 12: Total Prevalent Population Of Prurigo Nodularis In France (2016-2027)
Figure 13: Total Diagnosed Prevalence Of Prurigo Nodularis In France (2016-2027)
Figure 14: Type-Specific Prevalent Population Of Prurigo Nodularis In France (2016-2027)
Figure 15: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In France (2016-2027)
Figure 16: Total Prevalent Population Of Prurigo Nodularis In Italy (2016-2027)
Figure 17: Total Diagnosed Prevalence Of Prurigo Nodularis In Italy (2016-2027)
Figure 18: Type-Specific Prevalent Population Of Prurigo Nodularis In Italy (2016-2027)
Figure 19: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In Italy (2016-2027)
Figure 20: Total Prevalent Population Of Prurigo Nodularis In Spain (2016-2027)
Figure 21: Total Diagnosed Prevalence Of Prurigo Nodularis In Spain (2016-2027)
Figure 22: Type-Specific Prevalent Population Of Prurigo Nodularis In Spain (2016-2027)
Figure 23: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In Spain (2016-2027)
Figure 24: Total Prevalent Population Of Prurigo Nodularis In The United Kingdom (2016-2027)
Figure 25: Total Diagnosed Prevalence Of Prurigo Nodularis In The United Kingdom (2016-2027)
Figure 26: Type-Specific Prevalent Population Of Prurigo Nodularis In The United Kingdom (2016-2027)
Figure 27: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In The Uk (2016-2027)
Figure 28: Total Prevalent Population Of Prurigo Nodularis In Japan (2016-2027)
Figure 29: Total Diagnosed Prevalence Of Prurigo Nodularis In Japan (2016-2027)
Figure 30: Type-Specific Prevalent Population Of Prurigo Nodularis In Japan (2016-2027)
Figure 31: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In Japan (2016-2027)
Figure 32: Unmet Needs Of Prurigo Nodularis
Figure 33: 7 Major Market Size Of Prurigo Nodularis In Usd Million (2016-2027)
Figure 34: Market Size Of Prurigo Nodularis By Therapies In 7mm In Usd Million (2016-2027)
Figure 35: Market Size Of Prurigo Nodularis In The United States, Usd Millions (2016-2027)
Figure 36: Market Size Of Prurigo Nodularis By Therapies In The United States, Usd Millions (2016-2027)
Figure 37: Market Size Of Prurigo Nodularis In Germany, Usd Millions (2016-2027)
Figure 38: Market Size Of Prurigo Nodularis By Therapies In Germany, Usd Millions (2016-2027)
Figure 39: Market Size Of Prurigo Nodularis In France, Usd Millions (2016-2027)
Figure 40: Market Size Of Prurigo Nodularis By Therapies In France, Usd Millions (2016-2027)
Figure 41: Market Size Of Prurigo Nodularis In Italy, Usd Millions (2016-2027)
Figure 42: Market Size Of Prurigo Nodularis By Therapies In Italy, Usd Millions (2016-2027)
Figure 43: Market Size Of Prurigo Nodularis In Spain, Usd Millions (2016-2027)
Figure 44: Market Size Of Prurigo Nodularis By Therapies In Spain, Usd Millions (2016-2027)
Figure 45: Market Size Of Prurigo Nodularis In The United Kingdom, Usd Millions (2016-2027)
Figure 46: Market Size Of Prurigo Nodularis By Therapies In The United Kingdom, Usd Millions (2016-2027)
Figure 47: Market Size Of Prurigo Nodularis In Japan, Usd Millions (2016-2027)
Figure 48: Market Size Of Prurigo Nodularis By Therapies In Japan, Usd Millions (2016-2027)
Figure 49: Market Drivers
Figure 50:Market Barriers
Figure 1: Prurigo Nodualris - Butterfly Sign – No Lesion On The Center Of The Back
Figure 2: Total Prevalent Patient Population Of Prurigo Nodularis In The 7mm (2016-2027)
Figure 3: Total Diagnosed Prevalent Patient Population Of Prurigo Nodularis In The 7mm (2016-2027)
Figure 4: Total Prevalent Population Of Prurigo Nodularis In The United States (2016-2027)
Figure 5: Total Diagnosed Prevalence Of Prurigo Nodularis In The United States (2016-2027)
Figure 6: Type-Specific Prevalent Population Of Prurigo Nodularis In The United States (2016-2027)
Figure 7: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In The United States (2016-2027)
Figure 8: Total Prevalent Population Of Prurigo Nodularis In Germany (2016-2027)
Figure 9: Total Diagnosed Prevalence Of Prurigo Nodularis In Germany (2016-2027)
Figure 10: Type-Specific Prevalent Population Of Prurigo Nodularis In Germany (2016-2027)
Figure 11: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In Germany (2016-2027)
Figure 12: Total Prevalent Population Of Prurigo Nodularis In France (2016-2027)
Figure 13: Total Diagnosed Prevalence Of Prurigo Nodularis In France (2016-2027)
Figure 14: Type-Specific Prevalent Population Of Prurigo Nodularis In France (2016-2027)
Figure 15: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In France (2016-2027)
Figure 16: Total Prevalent Population Of Prurigo Nodularis In Italy (2016-2027)
Figure 17: Total Diagnosed Prevalence Of Prurigo Nodularis In Italy (2016-2027)
Figure 18: Type-Specific Prevalent Population Of Prurigo Nodularis In Italy (2016-2027)
Figure 19: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In Italy (2016-2027)
Figure 20: Total Prevalent Population Of Prurigo Nodularis In Spain (2016-2027)
Figure 21: Total Diagnosed Prevalence Of Prurigo Nodularis In Spain (2016-2027)
Figure 22: Type-Specific Prevalent Population Of Prurigo Nodularis In Spain (2016-2027)
Figure 23: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In Spain (2016-2027)
Figure 24: Total Prevalent Population Of Prurigo Nodularis In The United Kingdom (2016-2027)
Figure 25: Total Diagnosed Prevalence Of Prurigo Nodularis In The United Kingdom (2016-2027)
Figure 26: Type-Specific Prevalent Population Of Prurigo Nodularis In The United Kingdom (2016-2027)
Figure 27: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In The Uk (2016-2027)
Figure 28: Total Prevalent Population Of Prurigo Nodularis In Japan (2016-2027)
Figure 29: Total Diagnosed Prevalence Of Prurigo Nodularis In Japan (2016-2027)
Figure 30: Type-Specific Prevalent Population Of Prurigo Nodularis In Japan (2016-2027)
Figure 31: Severity Specific Diagnosed Prevalent Population Of Prurigo Nodularis In Japan (2016-2027)
Figure 32: Unmet Needs Of Prurigo Nodularis
Figure 33: 7 Major Market Size Of Prurigo Nodularis In Usd Million (2016-2027)
Figure 34: Market Size Of Prurigo Nodularis By Therapies In 7mm In Usd Million (2016-2027)
Figure 35: Market Size Of Prurigo Nodularis In The United States, Usd Millions (2016-2027)
Figure 36: Market Size Of Prurigo Nodularis By Therapies In The United States, Usd Millions (2016-2027)
Figure 37: Market Size Of Prurigo Nodularis In Germany, Usd Millions (2016-2027)
Figure 38: Market Size Of Prurigo Nodularis By Therapies In Germany, Usd Millions (2016-2027)
Figure 39: Market Size Of Prurigo Nodularis In France, Usd Millions (2016-2027)
Figure 40: Market Size Of Prurigo Nodularis By Therapies In France, Usd Millions (2016-2027)
Figure 41: Market Size Of Prurigo Nodularis In Italy, Usd Millions (2016-2027)
Figure 42: Market Size Of Prurigo Nodularis By Therapies In Italy, Usd Millions (2016-2027)
Figure 43: Market Size Of Prurigo Nodularis In Spain, Usd Millions (2016-2027)
Figure 44: Market Size Of Prurigo Nodularis By Therapies In Spain, Usd Millions (2016-2027)
Figure 45: Market Size Of Prurigo Nodularis In The United Kingdom, Usd Millions (2016-2027)
Figure 46: Market Size Of Prurigo Nodularis By Therapies In The United Kingdom, Usd Millions (2016-2027)
Figure 47: Market Size Of Prurigo Nodularis In Japan, Usd Millions (2016-2027)
Figure 48: Market Size Of Prurigo Nodularis By Therapies In Japan, Usd Millions (2016-2027)
Figure 49: Market Drivers
Figure 50:Market Barriers
